MX2022004572A - Conjugados farmacologicos de ligandos peptidicos biciclicos. - Google Patents

Conjugados farmacologicos de ligandos peptidicos biciclicos.

Info

Publication number
MX2022004572A
MX2022004572A MX2022004572A MX2022004572A MX2022004572A MX 2022004572 A MX2022004572 A MX 2022004572A MX 2022004572 A MX2022004572 A MX 2022004572A MX 2022004572 A MX2022004572 A MX 2022004572A MX 2022004572 A MX2022004572 A MX 2022004572A
Authority
MX
Mexico
Prior art keywords
drug conjugates
peptide ligand
ligand drug
bicyclic peptide
relates
Prior art date
Application number
MX2022004572A
Other languages
English (en)
Spanish (es)
Inventor
Gemma Mudd
Paul Beswick
Michael Rigby
Original Assignee
Bicycletx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bicycletx Ltd filed Critical Bicycletx Ltd
Publication of MX2022004572A publication Critical patent/MX2022004572A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2022004572A 2019-10-15 2020-10-15 Conjugados farmacologicos de ligandos peptidicos biciclicos. MX2022004572A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201914872A GB201914872D0 (en) 2019-10-15 2019-10-15 Bicyclic peptide ligand drug conjugates
PCT/GB2020/052590 WO2021074622A1 (en) 2019-10-15 2020-10-15 Bicyclic peptide ligand drug conjugates

Publications (1)

Publication Number Publication Date
MX2022004572A true MX2022004572A (es) 2022-05-06

Family

ID=68619460

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004572A MX2022004572A (es) 2019-10-15 2020-10-15 Conjugados farmacologicos de ligandos peptidicos biciclicos.

Country Status (12)

Country Link
US (1) US20240173422A1 (OSRAM)
EP (1) EP4045089A1 (OSRAM)
JP (1) JP2022552839A (OSRAM)
KR (1) KR20220088416A (OSRAM)
CN (1) CN114901317A (OSRAM)
AU (1) AU2020367325A1 (OSRAM)
BR (1) BR112022007099A2 (OSRAM)
CA (1) CA3154672A1 (OSRAM)
GB (1) GB201914872D0 (OSRAM)
IL (1) IL292113A (OSRAM)
MX (1) MX2022004572A (OSRAM)
WO (1) WO2021074622A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102754019B1 (ko) 2014-10-29 2025-01-14 바이시클러드 리미티드 Mt1-mmp에 특이적인 바이사이클릭 펩타이드 리간드
CN111032678A (zh) 2017-06-26 2020-04-17 拜西克尔德有限公司 具有可检测部分的双环肽配体和其用途
ES2926195T3 (es) 2017-08-04 2022-10-24 Bicycletx Ltd Ligandos peptídicos bicíclicos específicos de CD137
AU2019224659A1 (en) 2018-02-23 2020-10-15 Bicycletx Limited Multimeric bicyclic peptide ligands
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
CN113474045A (zh) 2018-12-21 2021-10-01 拜斯科技术开发有限公司 Pd-l1特异性的双环肽配体
US12551567B2 (en) 2018-12-21 2026-02-17 Bicyclerd Limited Bicyclic peptide ligands specific for PD-L1
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
CA3189761A1 (en) 2020-08-03 2022-02-10 Gemma Mudd Peptide-based linkers
GB202016331D0 (en) * 2020-10-15 2020-12-02 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
CN118215672A (zh) * 2021-06-01 2024-06-18 南京明德新药研发有限公司 多肽偶联药物及其应用
AU2022356942B2 (en) 2021-09-29 2025-07-03 Conjustar (Zhuhai) Biologics Co., Ltd. Tricyclic polypeptide conjugated drug and use thereof
GB202114279D0 (en) * 2021-10-06 2021-11-17 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
CN118201627A (zh) * 2021-10-19 2024-06-14 西藏海思科制药有限公司 Nectin-4的双环肽配体及其用途
CN116768978A (zh) * 2022-03-11 2023-09-19 上海智肽生物科技有限公司 Nectin-4靶向肽化合物及其药物偶联物
CN117003830A (zh) * 2023-08-04 2023-11-07 湖南中晟全肽生化有限公司 靶向Nectin-4的多肽及其用途
CN119701000A (zh) * 2024-12-25 2025-03-28 中国人民解放军空军军医大学 一类多肽偶联药物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
PT1844337E (pt) 2005-01-24 2014-04-03 Pepscan Systems Bv Compostos ligantes, compostos imunogénicos e peptidomiméticos
WO2009098450A2 (en) 2008-02-05 2009-08-13 Medical Research Council Methods and compositions
KR102754019B1 (ko) 2014-10-29 2025-01-14 바이시클러드 리미티드 Mt1-mmp에 특이적인 바이사이클릭 펩타이드 리간드
AU2019224659A1 (en) * 2018-02-23 2020-10-15 Bicycletx Limited Multimeric bicyclic peptide ligands
WO2019193328A1 (en) * 2018-04-04 2019-10-10 Bicycletx Limited Heterotandem bicyclic peptide complexes
US11180531B2 (en) * 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4

Also Published As

Publication number Publication date
CA3154672A1 (en) 2021-04-22
KR20220088416A (ko) 2022-06-27
GB201914872D0 (en) 2019-11-27
EP4045089A1 (en) 2022-08-24
JP2022552839A (ja) 2022-12-20
WO2021074622A1 (en) 2021-04-22
AU2020367325A1 (en) 2022-05-26
BR112022007099A2 (pt) 2022-07-05
CN114901317A (zh) 2022-08-12
US20240173422A1 (en) 2024-05-30
IL292113A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
PH12020552179A1 (en) Bicyclic peptide ligands specific for nectin-4
PH12020550929A1 (en) Bicyclic peptide ligands specific for epha2
WO2022148974A3 (en) Bicyclic peptide ligands specific for nk cells
MX2021013669A (es) Ligandos peptidicos biciclicos especificos para ox40.
BR112022007099A2 (pt) Conjugados de fármaco de ligante de peptídeo bicíclico
SA520420008B1 (ar) جزيئات ترابطية ببتيدية ثنائية الحلقات متعددة الوحدات
MX2021006991A (es) Ligandos peptidicos biciclicos especificos para metaloproteasa tipo 1 de membrana (mt1-mmp).
EA202191651A1 (ru) Бициклические пептидные лиганды, специфичные к mt1-mmp
ZA202001564B (en) Anti- folate receptor alpha antibody conjugates and their uses
MX2021002969A (es) Proteinas de union a nkg2d, cd16, y egfr, ccr4 o pd-l1.
MX2024005855A (es) Procedimientos para tratar el cancer.
MX2020010444A (es) Complejos de péptidos bicíclicos en heterotándem.
MX395142B (es) Marcadores selectivamente desregulados en celulas t reguladoras, infiltrantes de tumores.
GEAP202114828A (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
WO2016022994A3 (en) High affinity pd-1 agents and methods of use
UA88146C2 (ru) Новые пептиды, которые связываются с рецептором эритропоэтина
MX2022005404A (es) Compuestos de fijación a il-2r e il-7r dual.
ZA202107947B (en) Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
EP4621067A3 (en) Recombinant modified fibroblast growth factors and therapeutic uses thereof
JOP20230109A1 (ar) أجسام مضادة ثقيلة السلسلة ترتبط مع مستقبل ألفا فولات
MX2023005624A (es) Ligandos peptidicos biciclicos especificos para el receptor de transferrina 1 (tfr1).
Błauż et al. Drug-selected cell line panels for evaluation of the pharmacokinetic consequences of multidrug resistance proteins
CY1123041T1 (el) Συνδυασμος κανρενοατης και εξενατιδης
BR112017000710A2 (pt) polipeptídeo isolado, polipeptídeo modificado de revestimento final isolado, composição de matéria, polipeptídeo de fusão isolado, composição farmacêutica, método de tratamento de uma doença inflamatória, uso do polipeptídeo isolado, polinucleotídeo isolado, estrutura de ácido nucleico, e método de determinação da potência de um lote do polipeptídeo isolado
EA202190105A1 (ru) Бициклические пептидные лиганды, специфичные к нектину-4